Navigation Links
Dissident Stockholder Ted Karkus Found to Have Undisclosed Financial Arrangements With Dr. Richard A. Rosenbloom, COO Of Quigley Pharma, From 2008 to Date of Proxy: Rosenbloom Suspended Without Pay Pending Further Investigation
Date:5/19/2009

DOYLESTOWN, Pa., May 19 /PRNewswire-FirstCall/ -- The Quigley Corporation, (Nasdaq: QGLY), www.quigleyco.com, today announced that it has uncovered an improper financial relationship between Ted Karkus and the Company's Quigley Pharma, Inc. wholly-owned subsidiary COO, Dr. Richard A. Rosenbloom. The Company has come into possession of documentary evidence of undisclosed payments from Karkus to Rosenbloom continuing at least since 2008.

The Company is investigating as to whether any material non-public information was communicated from Rosenbloom to Karkus.

In April of 2008, Karkus solicited Charles Phillips, COO of The Quigley Corporation since 1989, to join him and others in a proxy fight to unseat the Management and Board of The Quigley Corporation. Phillips rejected the Karkus proposal. Shortly after this rejection, Karkus entered into a financial arrangement with Rosenbloom.

In a case brought by the Company in the Eastern District Court of Pennsylvania against Karkus and his slate of proposed directors, Karkus answered under oath "no" in his deposition when asked if he had any financial or other arrangements with any member of The Quigley Corporation's staff.

All employees of The Quigley Corporation received a notice in May of 2008 requiring that any contact with any shareholder be communicated to Management and memorialized. On April 13, 2009 the Company sent the same notice to all employees asking for written responses. Dr. Rosenbloom stated that he had no contact with any shareholder and, in particular, had no contact with Ted Karkus.

Guy J. Quigley, Chairman, President and Chief Executive Officer of The Quigley Corporation, stated, "On two separate occasions I contacted the
'/>"/>

SOURCE The Quigley Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan
2. Conseco Responds to RiskMetrics Groups Recommendation on Dissident Director Nominee
3. The Quigley Corporation Issues Open Letter to Stockholders; Urges Stockholders to Reject Dissident Ted Karkus Solicitation Efforts
4. LCA-Vision Announces Termination of Consent Solicitation and Withdrawal of Dissident Slate of Director Nominees
5. RiskMetrics Affirms Recommendation that Stockholders Support LCA-Vision Board of Directors and Reject All Proposals by Dissident Joffe Group
6. Leading Proxy Advisory Firm RiskMetrics Recommends Shareholders Support LCA-Vision Board of Directors and Reject All Proposals by Dissident Joffe Group
7. Glass Lewis Recommends Shareholders Support LCA-Vision Board of Directors and Reject All Three Proposals by Dissident Joffe Group
8. Smart Balance, Inc. to Hold Annual Meeting of Stockholders on May 20, 2009
9. Apex Bioventures Acquisition Corp. Sets Date for Special Meeting of Stockholders to Approve Dissolution
10. CPC Corrects Time of Conference Call for Annual Meeting of Stockholders
11. AMERIGROUP Corporation to Webcast Annual Meeting of Stockholders on May 7, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... have identified new pain relief targets that could ... BBSRC-funded researchers at King,s College London made the ... in the periphery of the body. , Dr ... identifying mechanisms underlying pain generation and our findings ... side effects." , One potential side effect of ...
(Date:4/17/2014)... 17, 2014) Two recent papers by a ... colleagues may help scientists develop treatments or vaccines ... Japanese encephalitis and other disease-causing flaviviruses. , Jeffrey ... molecular genetics at the School of Medicine and ... Medical Institute, and colleagues recently published articles in ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
(Date:4/17/2014)... Medicine (BUSM) have discovered that the anti-seizure drug ... The findings, reported in the American Journal ... to more effective treatments for alcoholism. , Excessive ... causes of illness and death in the U.S. ... the productivity of workers and necessitating huge health ...
(Date:4/17/2014)... (17 April 2014) Population Council scientists and their partners ... stable, and can prevent the transmission of multiple sexually ... in animals: HIV, herpes simplex virus 2 (HSV-2), and ... first data that the gel is effective against multiple ... in the vagina against all three viruses of at ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
... Health and the University of Colorado Denver have discovered a ... acute lung injury. Acute lung injury (ALI) is often caused ... in the blood, and fluid in the lungs. It is ... afflicting almost 200,000 people in the United States each year, ...
... Pharos Innovations, a pioneer in,assisting clients to ... a device-free remote monitoring platform,today announced it is ... of two key appointments in medical informatics and ... http://www.newscom.com/cgi-bin/prnh/20080306/AQTH086LOGO ) , ...
... N.Y., Jan. 16 Bausch & Lomb, the ... Valenti, III, will join Bausch & Lomb as ... month."Pete possesses deep leadership experience, as well as ... Stuart Heap, corporate vice president and global president, ...
... 16 /PRNewswire-FirstCall/ - Thomas E. Gardner, Chairman, announced ... appointed to the NUCRYST Pharmaceuticals, Board of Directors. ... Executive Officer of The Westaim Corporation ("Westaim"), NUCRYST,s ... common shares. Prior to his appointment as President ...
... 16 /PRNewswire-Asia-FirstCall/ -- Mindray Medical,International Limited (NYSE: ... of medical devices worldwide, today announced updates on ... and international markets in,2009. , ... of ten products, achieving the goals,for new product ...
... in Guangdong ProvincePROVO, Utah, Jan. 15 Nu Skin ... that it has received official notification from the Chinese ... selling activities in four cities in the Guangdong province ... Skin Enterprises the opportunity to offer a direct selling ...
Cached Medicine News:Health News:Gene associated with reduced mortality from acute lung injury 2Health News:Pharos Innovations Strengthens Leadership Team, Informatics Program 2Health News:Pharos Innovations Strengthens Leadership Team, Informatics Program 3Health News:Bausch & Lomb Names Peter Valenti, III, as President, North America, Vision Care 2Health News:NUCRYST Pharmaceuticals appoints a new director 2Health News:NUCRYST Pharmaceuticals appoints a new director 3Health News:Mindray Medical Achieves 2008 Product Development Goals and Announces Strong Pipeline for 2009 2Health News:Mindray Medical Achieves 2008 Product Development Goals and Announces Strong Pipeline for 2009 3Health News:Mindray Medical Achieves 2008 Product Development Goals and Announces Strong Pipeline for 2009 4Health News:Mindray Medical Achieves 2008 Product Development Goals and Announces Strong Pipeline for 2009 5Health News:Nu Skin Enterprises Receives Broader Direct Selling Authorization in China 2
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... report results for the fourth quarter of 2013 on Monday, ... scheduled for release after the close of trading. ... a conference call to discuss the operating highlights and financial ...
(Date:1/14/2014)... Brandeis Medical Center, led by Dr. Emmanuel Brandeis , offers ... tattoo removal experience with the advanced Astanza Duality laser and a ... cosmetic services with cutting edge medical technology and offering expert medical ... has seen a dramatic increase in the presence of tattoo ...
(Date:1/14/2014)... Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC Screw ... with accompanying instrumentation to place and insert the screw ... soft tissue (e.g. ligament) repair or reconstruction as it ... (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... 5 Virtual Health Technologies, Inc. (OTC Bulletin Board: VHGI) ... Intent to sell all health care related assets to Wound ... be paid $1,000,000 in cash and debt, 4,000,000 shares of ... VHGI. WNDM closed at $2.00 per share on 11/4/09 ...
... FRANCISCO, Calif., Nov. 5 Sunesis Pharmaceuticals, Inc. (Nasdaq: ... and Drug Administration has granted voreloxin orphan drug designation ... is currently conducting two Phase 2 clinical trials of ... of voreloxin in newly diagnosed elderly AML patients unlikely ...
Cached Medicine Technology:OTCBB-VHGI Announces LOI to Sell Certain Assets for $10 Million Cash/Stock to WNDM; With Stock Dividend to be Distributed to Shareholders in 2010 2OTCBB-VHGI Announces LOI to Sell Certain Assets for $10 Million Cash/Stock to WNDM; With Stock Dividend to be Distributed to Shareholders in 2010 3Sunesis' Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia 2Sunesis' Voreloxin Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia 3
... firm support and stabilization for non-operable hip ... total hip arthroplasty. Neoprene padding is secured ... wicking interface. This brace may be ordered ... Genesis joints. , ,POSTERIOR PANEL: ...
... Philippon Post-Op Hip Brace was developed in ... of Sports Medicine/Hip Disorders at the University ... as well as abduction and adduction in ... brace can also lock in any position ...
... The B3 Triplanar hip ... planes; Flexion - extension, abduction ... standard on our Boston Post-Op ... on our custom Hip Spicas ...
... Abduction and rotation for ... and fractures. Preset at ... adjustable flexion and extension ... back panel. Available in ...
Medicine Products: